Cargando…

High Prevalence of Anti–Severe Acute Respiratory Syndrome Coronavirus 2 (Anti–SARS-CoV-2) Antibodies After the First Wave of Coronavirus Disease 2019 (COVID-19) in Kinshasa, Democratic Republic of the Congo: Results of a Cross-sectional Household-Based Survey

BACKGROUND: In October 2020, after the first wave of coronavirus disease 2019 (COVID-19), only 8290 confirmed cases were reported in Kinshasa, Democratic Republic of the Congo, but the real prevalence remains unknown. To guide public health policies, we aimed to describe the prevalence of severe acu...

Descripción completa

Detalles Bibliográficos
Autores principales: Nkuba, Antoine N, Makiala, Sheila M, Guichet, Emilande, Tshiminyi, Paul M, Bazitama, Yannick M, Yambayamba, Marc K, Kazenza, Benito M, Kabeya, Trésor M, Matungulu, Elysee B, Baketana, Lionel K, Mitongo, Naomi M, Thaurignac, Guillaume, Leendertz, Fabian H, Vanlerberghe, Veerle, Pelloquin, Raphaël, Etard, Jean-François, Maman, David, Mbala, Placide K, Ayouba, Ahidjo, Peeters, Martine, Muyembe, Jean-Jacques T, Delaporte, Eric, Ahuka, Steve M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8244674/
https://www.ncbi.nlm.nih.gov/pubmed/34089598
http://dx.doi.org/10.1093/cid/ciab515
_version_ 1783715977503965184
author Nkuba, Antoine N
Makiala, Sheila M
Guichet, Emilande
Tshiminyi, Paul M
Bazitama, Yannick M
Yambayamba, Marc K
Kazenza, Benito M
Kabeya, Trésor M
Matungulu, Elysee B
Baketana, Lionel K
Mitongo, Naomi M
Thaurignac, Guillaume
Leendertz, Fabian H
Vanlerberghe, Veerle
Pelloquin, Raphaël
Etard, Jean-François
Maman, David
Mbala, Placide K
Ayouba, Ahidjo
Peeters, Martine
Muyembe, Jean-Jacques T
Delaporte, Eric
Ahuka, Steve M
author_facet Nkuba, Antoine N
Makiala, Sheila M
Guichet, Emilande
Tshiminyi, Paul M
Bazitama, Yannick M
Yambayamba, Marc K
Kazenza, Benito M
Kabeya, Trésor M
Matungulu, Elysee B
Baketana, Lionel K
Mitongo, Naomi M
Thaurignac, Guillaume
Leendertz, Fabian H
Vanlerberghe, Veerle
Pelloquin, Raphaël
Etard, Jean-François
Maman, David
Mbala, Placide K
Ayouba, Ahidjo
Peeters, Martine
Muyembe, Jean-Jacques T
Delaporte, Eric
Ahuka, Steve M
author_sort Nkuba, Antoine N
collection PubMed
description BACKGROUND: In October 2020, after the first wave of coronavirus disease 2019 (COVID-19), only 8290 confirmed cases were reported in Kinshasa, Democratic Republic of the Congo, but the real prevalence remains unknown. To guide public health policies, we aimed to describe the prevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunoglobulin G (IgG) antibodies in the general population in Kinshasa. METHODS: We conducted a cross-sectional, household-based serosurvey between 22 October 2020 and 8 November 2020. Participants were interviewed at home and tested for antibodies against SARS-CoV-2 spike and nucleocapsid proteins in a Luminex-based assay. A positive serology was defined as a sample that reacted with both SARS-CoV-2 proteins (100% sensitivity, 99.7% specificity). The overall weighted, age-standardized prevalence was estimated and the infection-to-case ratio was calculated to determine the proportion of undiagnosed SARS-CoV-2 infections. RESULTS: A total of 1233 participants from 292 households were included (mean age, 32.4 years; 764 [61.2%] women). The overall weighted, age-standardized SARS-CoV-2 seroprevalence was 16.6% (95% CI: 14.0–19.5%). The estimated infection-to-case ratio was 292:1. Prevalence was higher among participants ≥40 years than among those <18 years (21.2% vs 14.9%, respectively; P < .05). It was also higher in participants who reported hospitalization than among those who did not (29.8% vs 16.0%, respectively; P < .05). However, differences were not significant in the multivariate model (P = .1). CONCLUSIONS: The prevalence of SARS-CoV-2 is much higher than the number of COVID-19 cases reported. These results justify the organization of a sequential series of serosurveys by public health authorities to adapt response measures to the dynamics of the pandemic.
format Online
Article
Text
id pubmed-8244674
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-82446742021-07-01 High Prevalence of Anti–Severe Acute Respiratory Syndrome Coronavirus 2 (Anti–SARS-CoV-2) Antibodies After the First Wave of Coronavirus Disease 2019 (COVID-19) in Kinshasa, Democratic Republic of the Congo: Results of a Cross-sectional Household-Based Survey Nkuba, Antoine N Makiala, Sheila M Guichet, Emilande Tshiminyi, Paul M Bazitama, Yannick M Yambayamba, Marc K Kazenza, Benito M Kabeya, Trésor M Matungulu, Elysee B Baketana, Lionel K Mitongo, Naomi M Thaurignac, Guillaume Leendertz, Fabian H Vanlerberghe, Veerle Pelloquin, Raphaël Etard, Jean-François Maman, David Mbala, Placide K Ayouba, Ahidjo Peeters, Martine Muyembe, Jean-Jacques T Delaporte, Eric Ahuka, Steve M Clin Infect Dis Major Articles and Commentaries BACKGROUND: In October 2020, after the first wave of coronavirus disease 2019 (COVID-19), only 8290 confirmed cases were reported in Kinshasa, Democratic Republic of the Congo, but the real prevalence remains unknown. To guide public health policies, we aimed to describe the prevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunoglobulin G (IgG) antibodies in the general population in Kinshasa. METHODS: We conducted a cross-sectional, household-based serosurvey between 22 October 2020 and 8 November 2020. Participants were interviewed at home and tested for antibodies against SARS-CoV-2 spike and nucleocapsid proteins in a Luminex-based assay. A positive serology was defined as a sample that reacted with both SARS-CoV-2 proteins (100% sensitivity, 99.7% specificity). The overall weighted, age-standardized prevalence was estimated and the infection-to-case ratio was calculated to determine the proportion of undiagnosed SARS-CoV-2 infections. RESULTS: A total of 1233 participants from 292 households were included (mean age, 32.4 years; 764 [61.2%] women). The overall weighted, age-standardized SARS-CoV-2 seroprevalence was 16.6% (95% CI: 14.0–19.5%). The estimated infection-to-case ratio was 292:1. Prevalence was higher among participants ≥40 years than among those <18 years (21.2% vs 14.9%, respectively; P < .05). It was also higher in participants who reported hospitalization than among those who did not (29.8% vs 16.0%, respectively; P < .05). However, differences were not significant in the multivariate model (P = .1). CONCLUSIONS: The prevalence of SARS-CoV-2 is much higher than the number of COVID-19 cases reported. These results justify the organization of a sequential series of serosurveys by public health authorities to adapt response measures to the dynamics of the pandemic. Oxford University Press 2021-06-05 /pmc/articles/PMC8244674/ /pubmed/34089598 http://dx.doi.org/10.1093/cid/ciab515 Text en © The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Major Articles and Commentaries
Nkuba, Antoine N
Makiala, Sheila M
Guichet, Emilande
Tshiminyi, Paul M
Bazitama, Yannick M
Yambayamba, Marc K
Kazenza, Benito M
Kabeya, Trésor M
Matungulu, Elysee B
Baketana, Lionel K
Mitongo, Naomi M
Thaurignac, Guillaume
Leendertz, Fabian H
Vanlerberghe, Veerle
Pelloquin, Raphaël
Etard, Jean-François
Maman, David
Mbala, Placide K
Ayouba, Ahidjo
Peeters, Martine
Muyembe, Jean-Jacques T
Delaporte, Eric
Ahuka, Steve M
High Prevalence of Anti–Severe Acute Respiratory Syndrome Coronavirus 2 (Anti–SARS-CoV-2) Antibodies After the First Wave of Coronavirus Disease 2019 (COVID-19) in Kinshasa, Democratic Republic of the Congo: Results of a Cross-sectional Household-Based Survey
title High Prevalence of Anti–Severe Acute Respiratory Syndrome Coronavirus 2 (Anti–SARS-CoV-2) Antibodies After the First Wave of Coronavirus Disease 2019 (COVID-19) in Kinshasa, Democratic Republic of the Congo: Results of a Cross-sectional Household-Based Survey
title_full High Prevalence of Anti–Severe Acute Respiratory Syndrome Coronavirus 2 (Anti–SARS-CoV-2) Antibodies After the First Wave of Coronavirus Disease 2019 (COVID-19) in Kinshasa, Democratic Republic of the Congo: Results of a Cross-sectional Household-Based Survey
title_fullStr High Prevalence of Anti–Severe Acute Respiratory Syndrome Coronavirus 2 (Anti–SARS-CoV-2) Antibodies After the First Wave of Coronavirus Disease 2019 (COVID-19) in Kinshasa, Democratic Republic of the Congo: Results of a Cross-sectional Household-Based Survey
title_full_unstemmed High Prevalence of Anti–Severe Acute Respiratory Syndrome Coronavirus 2 (Anti–SARS-CoV-2) Antibodies After the First Wave of Coronavirus Disease 2019 (COVID-19) in Kinshasa, Democratic Republic of the Congo: Results of a Cross-sectional Household-Based Survey
title_short High Prevalence of Anti–Severe Acute Respiratory Syndrome Coronavirus 2 (Anti–SARS-CoV-2) Antibodies After the First Wave of Coronavirus Disease 2019 (COVID-19) in Kinshasa, Democratic Republic of the Congo: Results of a Cross-sectional Household-Based Survey
title_sort high prevalence of anti–severe acute respiratory syndrome coronavirus 2 (anti–sars-cov-2) antibodies after the first wave of coronavirus disease 2019 (covid-19) in kinshasa, democratic republic of the congo: results of a cross-sectional household-based survey
topic Major Articles and Commentaries
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8244674/
https://www.ncbi.nlm.nih.gov/pubmed/34089598
http://dx.doi.org/10.1093/cid/ciab515
work_keys_str_mv AT nkubaantoinen highprevalenceofantisevereacuterespiratorysyndromecoronavirus2antisarscov2antibodiesafterthefirstwaveofcoronavirusdisease2019covid19inkinshasademocraticrepublicofthecongoresultsofacrosssectionalhouseholdbasedsurvey
AT makialasheilam highprevalenceofantisevereacuterespiratorysyndromecoronavirus2antisarscov2antibodiesafterthefirstwaveofcoronavirusdisease2019covid19inkinshasademocraticrepublicofthecongoresultsofacrosssectionalhouseholdbasedsurvey
AT guichetemilande highprevalenceofantisevereacuterespiratorysyndromecoronavirus2antisarscov2antibodiesafterthefirstwaveofcoronavirusdisease2019covid19inkinshasademocraticrepublicofthecongoresultsofacrosssectionalhouseholdbasedsurvey
AT tshiminyipaulm highprevalenceofantisevereacuterespiratorysyndromecoronavirus2antisarscov2antibodiesafterthefirstwaveofcoronavirusdisease2019covid19inkinshasademocraticrepublicofthecongoresultsofacrosssectionalhouseholdbasedsurvey
AT bazitamayannickm highprevalenceofantisevereacuterespiratorysyndromecoronavirus2antisarscov2antibodiesafterthefirstwaveofcoronavirusdisease2019covid19inkinshasademocraticrepublicofthecongoresultsofacrosssectionalhouseholdbasedsurvey
AT yambayambamarck highprevalenceofantisevereacuterespiratorysyndromecoronavirus2antisarscov2antibodiesafterthefirstwaveofcoronavirusdisease2019covid19inkinshasademocraticrepublicofthecongoresultsofacrosssectionalhouseholdbasedsurvey
AT kazenzabenitom highprevalenceofantisevereacuterespiratorysyndromecoronavirus2antisarscov2antibodiesafterthefirstwaveofcoronavirusdisease2019covid19inkinshasademocraticrepublicofthecongoresultsofacrosssectionalhouseholdbasedsurvey
AT kabeyatresorm highprevalenceofantisevereacuterespiratorysyndromecoronavirus2antisarscov2antibodiesafterthefirstwaveofcoronavirusdisease2019covid19inkinshasademocraticrepublicofthecongoresultsofacrosssectionalhouseholdbasedsurvey
AT matunguluelyseeb highprevalenceofantisevereacuterespiratorysyndromecoronavirus2antisarscov2antibodiesafterthefirstwaveofcoronavirusdisease2019covid19inkinshasademocraticrepublicofthecongoresultsofacrosssectionalhouseholdbasedsurvey
AT baketanalionelk highprevalenceofantisevereacuterespiratorysyndromecoronavirus2antisarscov2antibodiesafterthefirstwaveofcoronavirusdisease2019covid19inkinshasademocraticrepublicofthecongoresultsofacrosssectionalhouseholdbasedsurvey
AT mitongonaomim highprevalenceofantisevereacuterespiratorysyndromecoronavirus2antisarscov2antibodiesafterthefirstwaveofcoronavirusdisease2019covid19inkinshasademocraticrepublicofthecongoresultsofacrosssectionalhouseholdbasedsurvey
AT thaurignacguillaume highprevalenceofantisevereacuterespiratorysyndromecoronavirus2antisarscov2antibodiesafterthefirstwaveofcoronavirusdisease2019covid19inkinshasademocraticrepublicofthecongoresultsofacrosssectionalhouseholdbasedsurvey
AT leendertzfabianh highprevalenceofantisevereacuterespiratorysyndromecoronavirus2antisarscov2antibodiesafterthefirstwaveofcoronavirusdisease2019covid19inkinshasademocraticrepublicofthecongoresultsofacrosssectionalhouseholdbasedsurvey
AT vanlerbergheveerle highprevalenceofantisevereacuterespiratorysyndromecoronavirus2antisarscov2antibodiesafterthefirstwaveofcoronavirusdisease2019covid19inkinshasademocraticrepublicofthecongoresultsofacrosssectionalhouseholdbasedsurvey
AT pelloquinraphael highprevalenceofantisevereacuterespiratorysyndromecoronavirus2antisarscov2antibodiesafterthefirstwaveofcoronavirusdisease2019covid19inkinshasademocraticrepublicofthecongoresultsofacrosssectionalhouseholdbasedsurvey
AT etardjeanfrancois highprevalenceofantisevereacuterespiratorysyndromecoronavirus2antisarscov2antibodiesafterthefirstwaveofcoronavirusdisease2019covid19inkinshasademocraticrepublicofthecongoresultsofacrosssectionalhouseholdbasedsurvey
AT mamandavid highprevalenceofantisevereacuterespiratorysyndromecoronavirus2antisarscov2antibodiesafterthefirstwaveofcoronavirusdisease2019covid19inkinshasademocraticrepublicofthecongoresultsofacrosssectionalhouseholdbasedsurvey
AT mbalaplacidek highprevalenceofantisevereacuterespiratorysyndromecoronavirus2antisarscov2antibodiesafterthefirstwaveofcoronavirusdisease2019covid19inkinshasademocraticrepublicofthecongoresultsofacrosssectionalhouseholdbasedsurvey
AT ayoubaahidjo highprevalenceofantisevereacuterespiratorysyndromecoronavirus2antisarscov2antibodiesafterthefirstwaveofcoronavirusdisease2019covid19inkinshasademocraticrepublicofthecongoresultsofacrosssectionalhouseholdbasedsurvey
AT peetersmartine highprevalenceofantisevereacuterespiratorysyndromecoronavirus2antisarscov2antibodiesafterthefirstwaveofcoronavirusdisease2019covid19inkinshasademocraticrepublicofthecongoresultsofacrosssectionalhouseholdbasedsurvey
AT muyembejeanjacquest highprevalenceofantisevereacuterespiratorysyndromecoronavirus2antisarscov2antibodiesafterthefirstwaveofcoronavirusdisease2019covid19inkinshasademocraticrepublicofthecongoresultsofacrosssectionalhouseholdbasedsurvey
AT delaporteeric highprevalenceofantisevereacuterespiratorysyndromecoronavirus2antisarscov2antibodiesafterthefirstwaveofcoronavirusdisease2019covid19inkinshasademocraticrepublicofthecongoresultsofacrosssectionalhouseholdbasedsurvey
AT ahukastevem highprevalenceofantisevereacuterespiratorysyndromecoronavirus2antisarscov2antibodiesafterthefirstwaveofcoronavirusdisease2019covid19inkinshasademocraticrepublicofthecongoresultsofacrosssectionalhouseholdbasedsurvey